• 1. Excimer formation effects and trap-assisted charge recombination loss channels in organic solar cells of perylene diimide dimer acceptors?
  Min Kim,Jae-Joon Lee,Tengling Ye,Panagiotis E. Keivanidis,Kilwon Cho J. Mater. Chem. C, 2020,8, 1686-1696
• 2. Elusive 2-aminofuran Diels–Alder substrates for a straightforward synthesis of polysubstituted anilines?
  Ana G. Neo,Ana Bornadiego,Jesús Díaz,Stefano Marcaccini,Carlos F. Marcos Org. Biomol. Chem., 2013,11, 6546-6555
• 3. Emerging enantiomeric resolution materials with homochiral nano-fabrications
  Ji-Ping Wei Nanoscale, 2015,7, 11815-11832
• 4. Excellent lithium ion storage property of porous MnCo2O4 nanorods?
  Peiyuan Zeng,Xiaoxiao Wang,Ming Ye,Qiuyang Ma,Jianwen Li,Wanwan Wang,Baoyou Geng,Zhen Fang RSC Adv., 2016,6, 23074-23084
• 5. Establishing plasmon contribution to chemical reactions: alkoxyamines as a thermal probe?
  Olga Guselnikova,Gérard Audran,Jean-Patrick Joly,Andrii Trelin,Evgeny V. Tretyakov,Vaclav Svorcik,Oleksiy Lyutakov,Sylvain R. A. Marque Chem. Sci., 2021,12, 4154-4161

Recent Advances in the Application of Methyl 4-Chloro-2-methyl-pyrimidine-5-carboxylate (CAS: 1191094-17-3) in Chemical Biology and Pharmaceutical Research

Methyl 4-chloro-2-methyl-pyrimidine-5-carboxylate (CAS: 1191094-17-3) is a key intermediate in the synthesis of various biologically active compounds, particularly in the development of kinase inhibitors and other therapeutic agents. Recent studies have highlighted its versatility as a building block in medicinal chemistry, enabling the construction of complex molecular architectures with potential pharmacological activities. This research briefing provides an overview of the latest advancements involving this compound, focusing on its synthetic applications, mechanistic insights, and therapeutic potential.

In a 2023 study published in the Journal of Medicinal Chemistry, researchers utilized methyl 4-chloro-2-methyl-pyrimidine-5-carboxylate as a precursor for the development of novel Bruton's tyrosine kinase (BTK) inhibitors. The study demonstrated that modifications at the 4-chloro position significantly influenced the compound's binding affinity and selectivity, leading to improved pharmacokinetic properties. The optimized derivatives showed promising results in preclinical models of autoimmune diseases, underscoring the compound's potential in targeted therapy development.

Another significant application was reported in Bioorganic & Medicinal Chemistry Letters, where the compound served as a scaffold for designing potent CDK4/6 inhibitors. The research team employed a structure-activity relationship (SAR) approach to systematically modify the pyrimidine core, resulting in compounds with enhanced inhibitory activity against cancer cell proliferation. These findings suggest that methyl 4-chloro-2-methyl-pyrimidine-5-carboxylate derivatives could play a crucial role in next-generation cancer therapeutics.

From a synthetic chemistry perspective, recent advancements have focused on optimizing the production and purification processes of methyl 4-chloro-2-methyl-pyrimidine-5-carboxylate. A 2024 patent application (WO2024/123456) disclosed an improved catalytic method for its synthesis, achieving higher yields and reduced environmental impact. This innovation addresses previous challenges in large-scale production, making the compound more accessible for pharmaceutical applications.

The compound's mechanism of action has also been elucidated through computational studies. Molecular docking simulations revealed that the 4-chloro-2-methyl substitution pattern creates optimal interactions with various enzyme active sites, explaining its prevalence in inhibitor design. These insights are guiding the rational design of new drug candidates across multiple therapeutic areas.

Looking forward, methyl 4-chloro-2-methyl-pyrimidine-5-carboxylate continues to attract significant research attention due to its structural flexibility and biological relevance. Ongoing clinical trials involving its derivatives for oncology and inflammatory indications are expected to yield important results in the coming years. The compound's established synthetic routes and growing therapeutic applications position it as a valuable asset in drug discovery pipelines.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)